Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 SEK | -4.95% | -6.76% | -37.94% |
04-25 | AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-10 | Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR). | CI |
Sales 2024 * | - | Sales 2025 * | 60 5.49 438.76 | Capitalization | 125M 11.48M 917M |
---|---|---|---|---|---|
Net income 2024 * | -46M -4.21M -336M | Net income 2025 * | -7M -641K -51.19M | EV / Sales 2024 * | - |
Net cash position 2024 * | 42.5M 3.89M 311M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2,090,263 x |
P/E ratio 2024 * |
6.73
x | P/E ratio 2025 * |
-1.84
x | Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 36.1% |
1 day | -4.46% | ||
1 week | -6.76% | ||
Current month | +6.04% | ||
1 month | +13.20% | ||
3 months | -40.98% | ||
6 months | -51.39% | ||
Current year | -37.94% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Jönsson
CEO | Chief Executive Officer | 56 | 07/01/20 |
Johan Sandin
FOU | Founder | 54 | 21/11/16 |
Birgitta Lundvik
DFI | Director of Finance/CFO | 57 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 31/12/16 | |
Ragnar Linder
BRD | Director/Board Member | 71 | 31/12/16 |
Ellen Donnelly
BRD | Director/Board Member | 50 | 31/12/17 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 1.92 | -4.95% | 53 471 |
26/04/24 | 2.02 | -1.46% | 191,004 |
25/04/24 | 2.05 | -2.38% | 186,896 |
24/04/24 | 2.1 | +5.79% | 117,624 |
23/04/24 | 1.985 | -4.11% | 55,256 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 10:09 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.94% | 11.44M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.79% | 22.15B | |
-17.37% | 21.02B | |
-7.98% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALZCUR Stock